title: Initial serum thyroid peroxidase antibodies and long-term outcomes in SREAT.
abstract: OBJECTIVE
  To quantify clinical outcome in patients with steroid-responsive encephalopathy and associated autoimmune thyroiditis (SREAT) after the acute phase and explore potential associations of initial serum thyroid peroxidase antibody titers (TPO-Abs) with outcome.
  
  
  METHODS
  Retrospective chart review of patients diagnosed with SREAT between 01/2005 and 05/2014 in a tertiary care center and followed in an affiliated autoimmune outpatient clinic. Outcome was quantified using the extended Glasgow Outcome Scale (GOS-E). We calculated Pearson's correlation coefficients to quantify associations with clinical outcome at follow-up.
  
  
  RESULTS
  Among 134 patients with encephalopathy of unknown etiology, we identified 13 patients diagnosed with SREAT. In two patients, the diagnosis was revised at subsequent hospitalization (NMDA-R encephalitis and adult-onset Still's disease). The median follow-up time was 11 months, and the median GOS-E was 6 (range 3-8). Higher serum TPO-Ab-titers correlated with more favorable outcomes (Pearson coefficient 0.65, P = 0.03).
  
  
  CONCLUSIONS
  A correlation between TPO-Ab-titers and outcome has not been reported previously and challenges the notion of a mere bystander role of TPO-Abs in SREAT.
authors.affiliation: Department of Neurology, Charité University Medicine Berlin, Berlin, Germany.
authors.forename: S
authors.initials: S
authors.lastname: Litmeier
authors.affiliation: Department of Neurology, Charité University Medicine Berlin, Berlin, Germany.|German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany.
authors.forename: H
authors.initials: H
authors.lastname: Prüss
authors.affiliation: Department of Neurology, University Medical Center of the Johannes Gutenberg University of Mainz, Mainz, Germany.
authors.forename: E
authors.initials: E
authors.lastname: Witsch
authors.affiliation: Department of Neurology, Charité University Medicine Berlin, Berlin, Germany. Jensjulianwitsch@gmail.com.
authors.forename: J
authors.initials: J
authors.lastname: Witsch
mesh_terms: D000328:Adult; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D001323:Autoantibodies / Q000032:analysis*; D004660:Encephalitis / Q000097:blood / Q000276:immunology* / Q000628:therapy*; D005260:Female; D005500:Follow-Up Studies; D023261:Glasgow Outcome Scale; D050031:Hashimoto Disease / Q000097:blood / Q000276:immunology* / Q000628:therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007453:Iodide Peroxidase / Q000097:blood / Q000276:immunology*; D008279:Magnetic Resonance Imaging; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D012189:Retrospective Studies; D013256:Steroids / Q000627:therapeutic use; D013967:Thyroiditis, Autoimmune / Q000097:blood / Q000276:immunology* / Q000628:therapy*; D016896:Treatment Outcome
chemical_list: D000893:Anti-Inflammatory Agents; D001323:Autoantibodies; D007166:Immunosuppressive Agents; D013256:Steroids; D007453:Iodide Peroxidase; D008727:Methotrexate
keywords: 
  SREAT
  ; autoantibodies; autoimmune diseases; encephalitis; hashimoto encephalopathy; steroid-responsive encephalopathy; thyroid microsomal antibodies; thyroid peroxidase antibodies